SARS-CoV-2 Pseudoviral Particles, Lambda Variant (Lineage C.37)

Catalog Number:
SARS-CoV-2 Pseudoviral Particles, replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein (the Lambda C.37 variant). (Mobile users please click "View Full Site" for details)
Price: $500.00
Detailed Description
Keyword: coronavirus, SARS, SARS-Cov, SARS-COV-2, covid19, covid-19, SARS pseudovirus, sars-cov-2 pseudovirus, sars-cov-2 spike, MLV, ace2, B.1.351, covid South Africa variant



SARS-CoV-2 Pseudoviral Particles, Lambda Variant (C.37)


The SARS-CoV-2 Pseudoviral Particles are replication-deficient Maloneymurine leukemia virus (MLV or MuLV) pseudotyped with the SARS-CoV-2 spike protein of the Lambda variant (C.37) (Accession ID: EPI_ISL_3274616) .
MLV-based virus system is a better choice than HIV-based lentivirus system for making pseudoviral particles in regards of lab safety and product quality. Gag-Pol is the only component from MLV.


Our Pseudovirus Particles generate robust chemiluminescent signals in cell assays when coupled with our firefly luciferase assay kit (Catalog # CA-L165), useful for 1) screening potential inhibitors to block SARS-CoV-2 entry and viral protein; 2) measuring the activity of and screening for neutralizing antibody against SARS-CoV-2. 


5 ml, for one multi-well plate. Pseudoviral particles per mL ~ 1.0E+08


 -70o C. Shipped on dry ice.


1. Amenable to HTS format (96-well, 384-well and 1536-well format). 
2. HEK293-hACE2 stable cell lines are available seperately (Cat.# CL-hACE2-001, CL-hACE2-002)

For Downloading


Our SARS-CoV-2 pseudovirus products have been tested in many COVID research work. Here are a few citations: 

1) A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerging Microbes & Infections, May 2021
2) Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. Vaccines, Feb. 2021
3) Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection. Clinical Infectious Diseases, Sept. 2020

Emergent SARS-CoV-2 Variants; The Delta and Lambda Variants

Mailing Lists